Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products
The use of live biotherapeutic products (LBPs), including single strains of beneficial probiotic bacteria or consortiums, is gaining traction as a viable option to treat inflammatory-mediated diseases like inflammatory bowel disease (IBD). However, LBPs’ persistence in the intestine is heterogeneous...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/11/5/738 |
| _version_ | 1827692445399252992 |
|---|---|
| author | Jiayu Ye Lauren A. E. Erland Sandeep K. Gill Stephanie L. Bishop Andrea Verdugo-Meza Susan J. Murch Deanna L. Gibson |
| author_facet | Jiayu Ye Lauren A. E. Erland Sandeep K. Gill Stephanie L. Bishop Andrea Verdugo-Meza Susan J. Murch Deanna L. Gibson |
| author_sort | Jiayu Ye |
| collection | DOAJ |
| description | The use of live biotherapeutic products (LBPs), including single strains of beneficial probiotic bacteria or consortiums, is gaining traction as a viable option to treat inflammatory-mediated diseases like inflammatory bowel disease (IBD). However, LBPs’ persistence in the intestine is heterogeneous since many beneficial bacteria lack mechanisms to tolerate the inflammation and the oxidative stress associated with IBD. We rationalized that optimizing LBPs with enhanced colonization and persistence in the inflamed intestine would help beneficial bacteria increase their bioavailability and sustain their beneficial responses. Our lab developed two bioengineered LBPs (SBT001/BioPersist and SBT002/BioColoniz) modified to enhance colonization or persistence in the inflamed intestine. In this study, we examined colon-derived metabolites via ultra-high performance liquid chromatography-mass spectrometry in colitic mice treated with either BioPersist or BioColoniz as compared to their unmodified parent strains (<i>Escherichia coli</i> Nissle 1917 [EcN] and <i>Lactobacillus reuteri</i>, respectively) or to each other. BioPersist administration resulted in lowered concentrations of inflammatory prostaglandins, decreased stress hormones such as adrenaline and corticosterone, increased serotonin, and decreased bile acid in comparison to EcN. In comparison to BioColoniz, BioPersist increased serotonin and antioxidant production, limited bile acid accumulation, and enhanced tissue restoration via activated purine and pyrimidine metabolism. These data generated several novel hypotheses for the beneficial roles that LBPs may play during colitis. |
| first_indexed | 2024-03-10T11:23:12Z |
| format | Article |
| id | doaj.art-afecd45791b5419ba9315758fff3ff39 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T11:23:12Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-afecd45791b5419ba9315758fff3ff392023-11-21T19:55:04ZengMDPI AGBiomolecules2218-273X2021-05-0111573810.3390/biom11050738Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic ProductsJiayu Ye0Lauren A. E. Erland1Sandeep K. Gill2Stephanie L. Bishop3Andrea Verdugo-Meza4Susan J. Murch5Deanna L. Gibson6Department of Biology, University of British Columbia, Syilx Okanagan Nation Territory, Kelowna, BC V1V1V7, CanadaDepartment of Chemistry, University of British Columbia, Syilx Okanagan Nation Territory, Kelowna, BC V1V1V7, CanadaDepartment of Biology, University of British Columbia, Syilx Okanagan Nation Territory, Kelowna, BC V1V1V7, CanadaDepartment of Chemistry, University of British Columbia, Syilx Okanagan Nation Territory, Kelowna, BC V1V1V7, CanadaDepartment of Biology, University of British Columbia, Syilx Okanagan Nation Territory, Kelowna, BC V1V1V7, CanadaDepartment of Chemistry, University of British Columbia, Syilx Okanagan Nation Territory, Kelowna, BC V1V1V7, CanadaDepartment of Biology, University of British Columbia, Syilx Okanagan Nation Territory, Kelowna, BC V1V1V7, CanadaThe use of live biotherapeutic products (LBPs), including single strains of beneficial probiotic bacteria or consortiums, is gaining traction as a viable option to treat inflammatory-mediated diseases like inflammatory bowel disease (IBD). However, LBPs’ persistence in the intestine is heterogeneous since many beneficial bacteria lack mechanisms to tolerate the inflammation and the oxidative stress associated with IBD. We rationalized that optimizing LBPs with enhanced colonization and persistence in the inflamed intestine would help beneficial bacteria increase their bioavailability and sustain their beneficial responses. Our lab developed two bioengineered LBPs (SBT001/BioPersist and SBT002/BioColoniz) modified to enhance colonization or persistence in the inflamed intestine. In this study, we examined colon-derived metabolites via ultra-high performance liquid chromatography-mass spectrometry in colitic mice treated with either BioPersist or BioColoniz as compared to their unmodified parent strains (<i>Escherichia coli</i> Nissle 1917 [EcN] and <i>Lactobacillus reuteri</i>, respectively) or to each other. BioPersist administration resulted in lowered concentrations of inflammatory prostaglandins, decreased stress hormones such as adrenaline and corticosterone, increased serotonin, and decreased bile acid in comparison to EcN. In comparison to BioColoniz, BioPersist increased serotonin and antioxidant production, limited bile acid accumulation, and enhanced tissue restoration via activated purine and pyrimidine metabolism. These data generated several novel hypotheses for the beneficial roles that LBPs may play during colitis.https://www.mdpi.com/2218-273X/11/5/738live biotherapeuticsgut–liver–brain axisinflammatory bowel diseaseimmunometabolism |
| spellingShingle | Jiayu Ye Lauren A. E. Erland Sandeep K. Gill Stephanie L. Bishop Andrea Verdugo-Meza Susan J. Murch Deanna L. Gibson Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products Biomolecules live biotherapeutics gut–liver–brain axis inflammatory bowel disease immunometabolism |
| title | Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products |
| title_full | Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products |
| title_fullStr | Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products |
| title_full_unstemmed | Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products |
| title_short | Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products |
| title_sort | metabolomics guided hypothesis generation for mechanisms of intestinal protection by live biotherapeutic products |
| topic | live biotherapeutics gut–liver–brain axis inflammatory bowel disease immunometabolism |
| url | https://www.mdpi.com/2218-273X/11/5/738 |
| work_keys_str_mv | AT jiayuye metabolomicsguidedhypothesisgenerationformechanismsofintestinalprotectionbylivebiotherapeuticproducts AT laurenaeerland metabolomicsguidedhypothesisgenerationformechanismsofintestinalprotectionbylivebiotherapeuticproducts AT sandeepkgill metabolomicsguidedhypothesisgenerationformechanismsofintestinalprotectionbylivebiotherapeuticproducts AT stephanielbishop metabolomicsguidedhypothesisgenerationformechanismsofintestinalprotectionbylivebiotherapeuticproducts AT andreaverdugomeza metabolomicsguidedhypothesisgenerationformechanismsofintestinalprotectionbylivebiotherapeuticproducts AT susanjmurch metabolomicsguidedhypothesisgenerationformechanismsofintestinalprotectionbylivebiotherapeuticproducts AT deannalgibson metabolomicsguidedhypothesisgenerationformechanismsofintestinalprotectionbylivebiotherapeuticproducts |